drugset / Trial / NCT06276101
NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and tolerability of HPV-16 and HPV-18-targeted DNA plasmid vaccine (NWRD08) in patients HPV-16 and/or HPV-18 related cervical HSIL.
Timeline
- Start
- 2024-05-07
- Primary completion
- 2025-02-19
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NWRD08 | Vaccine | 1 mg | Intramuscular |
| Subject | NWRD08 | Vaccine | 4 mg | Intramuscular |
| Subject | NWRD08 | Vaccine | 8 mg | Intramuscular |